Non-Hodgkin Lymphoma (NHL) — RepurpOS

Disease overview

Alterations

188

Molecular (A)

100

Clinical (B–E)

Direct drugs

494

Via biomarker

244

Natural agents

Natural products

Merged ranked

734

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Examine.com, disease_db_100 · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Indolent NHL (follicular): spontaneous remission in 20-30% of early-stage, allowing watch-and-wait; aggressive NHL (DLBCL): rapidly lethal without treatment in weeks-months

Best-intervention remission

DLBCL with R-CHOP: 60-70% cure rate; Pola-R-CHP (polatuzumab): 27% improvement in 2-year PFS (POLARIX); DLBCL relapsed: axicabtagene ciloleucel (axi-cel) CAR-T: 40-50% long-term remission; follicular lymphoma: obinutuzumab + chemotherapy 85-90% response, durable

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Variable by subtype; DLBCL has genuinely curative potential; indolent NHL remains manageable but generally incurable with current therapy

Primary barrier

access (CAR-T) + biological (indolent NHL)

Barrier detail: CAR-T therapy is transformative in relapsed DLBCL but manufacturing time (2-3 weeks), cost ($400K+), and centre requirements limit access; bispecific antibodies (epcoritamab, glofitamab) offer off-the-shelf alternative

Last SoC change: 2022-2023 — bispecific antibodies (epcoritamab, glofitamab) approved for relapsed DLBCL; CAR-T as second-line (ZUMA-7, TRANSFORM) since 2022; Pola-R-CHP first-line 2023; R-CHOP since 2000 (CHOP since 1970s)

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0018908

Right to Try Relevance Critical

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Non-Hodgkin Lymphoma may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

Phase 3: 40

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

188

Actionable

Pipeline Compounds (Top 6)

Aldesleukin, Allopurinol, Asparaginase, Bendamustine, Bevacizumab, Bleomycin

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

Showing 80 of 188 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abdominal pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal bone marrow cell morphology	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal lymph node morphology	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal nasolacrimal system morphology	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of the gastrointestinal tract	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of the thyroid gland	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Acute kidney injury	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Acute lymphoblastic leukemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anorexia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Autoimmunity	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
B-cell lymphoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Burkitt lymphoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cellular immunodeficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chills	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chronic lymphatic leukemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Congestive heart failure	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Constipation	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cryoglobulinemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cutis laxa	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Diarrhea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Eczematoid dermatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Erythema	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Erythematous papule	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Erythematous plaque	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Facial edema	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Fatigue	Functional	Functional test	—	—	Moderate	HPO, Monarch	HPO
Fever	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gastric lymphoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gastrointestinal hemorrhage	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hearing impairment	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hemophagocytosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hepatomegaly	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hepatosplenomegaly	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hodgkin lymphoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypercalcemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hyperhidrosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypertriglyceridemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypofibrinogenemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Immunodeficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Impaired lymphocyte transformation with phytohemagglutinin	Functional	Functional test	—	—	Moderate	HPO, Monarch	HPO
Increased circulating ferritin concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Leukemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Lymphadenopathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Lymphoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Mediastinal lymphadenopathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Migraine	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Monoclonal immunoglobulin M proteinemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Multifocal epileptiform discharges	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nausea and vomiting	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neoplasm of the skin	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nephrocalcinosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pallor	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pancytopenia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Panniculitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Periorbital edema	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Peripheral neuropathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pleural effusion	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Polyclonal elevation of IgM	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Polyneuropathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Posterior uveitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pruritus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Psoriasiform dermatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pulmonary infiltrates	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Purpura	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Recurrent respiratory infections	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Reduced consciousness	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Redundant skin	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Renal insufficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Skin plaque	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Splenomegaly	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Stiff skin	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Subcutaneous panniculitis-like T-cell lymphoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
T-cell acute lymphoblastic leukemias	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Urticaria	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Vertigo	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Visual impairment	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Weight loss	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ALK ALK receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
4-PHENYLBUTYRIC ACID		Gene-targeted
ABEMACICLIB		Gene-targeted
ABIRATERONE ACETATE		Gene-targeted
ACALABRUTINIB	inhibitor; inhibitor	Gene-targeted
ACALABRUTINIB MALEATE	inhibitor	Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
ACYCLOVIR		Gene-targeted
ADENOSINE TRIPHOSPHATE		Gene-targeted
AFATINIB		Gene-targeted
ALECTINIB	inhibitor; inhibitor	Gene-targeted
ALECTINIB HYDROCHLORIDE	inhibitor	Gene-targeted
ALPELISIB		Gene-targeted
AMIKACIN		Gene-targeted
AMPHETAMINE	None	Gene-targeted
ASCIMINIB	modulator; inhibitor	Gene-targeted
ASCIMINIB HYDROCHLORIDE	inhibitor	Gene-targeted
ATEZOLIZUMAB		Gene-targeted
AVELUMAB		Gene-targeted
AXITINIB		Gene-targeted
AZACITIDINE		Gene-targeted
BENDAMUSTINE		Gene-targeted
BEVACIZUMAB		Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BINIMETINIB		Gene-targeted
BLINATUMOMAB		Gene-targeted
BORTEZOMIB		Gene-targeted
BOSUTINIB	inhibitor; inhibitor	Gene-targeted
BOSUTINIB MONOHYDRATE	inhibitor	Gene-targeted
BRENTUXIMAB VEDOTIN		Gene-targeted
BRIGATINIB	inhibitor; inhibitor	Gene-targeted
BUSULFAN		Gene-targeted
CABOZANTINIB S-MALATE		Gene-targeted
CAMPTOTHECIN		Gene-targeted
CAPECITABINE		Gene-targeted
CAPMATINIB		Gene-targeted
CARBACHOL	None	Gene-targeted
CARBAMAZEPINE		Gene-targeted
CARBOPLATIN		Gene-targeted
CELECOXIB		Gene-targeted
CEMIPLIMAB		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
EPIRUBICIN	Small molecule	Approved	Strong	100	8 trials 10 Trial pubs 5 RCT View evidence Registry trials NCT06739265 — Golidocitinib Plus CHOP in Newly Diagnosed PTCL (RECRUITING) PHASE1, PHASE2 NCT03268889 — Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) (UNKNOWN) NA NCT04152577 — R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL (UNKNOWN) PHASE4 NCT00869284 — Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas (COMPLETED) PHASE2 NCT03151044 — R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL (UNKNOWN) PHASE3 NCT05097443 — Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (UNKNOWN) PHASE3 NCT05075460 — Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma (UNKNOWN) PHASE3 NCT02871869 — Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma (UNKNOWN) PHASE2, PHASE3 Published literature Randomized controlled trial Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2005) Randomized controlled trial [Comparison of effectiveness of adriamycin and epirubicin administered in the CHOP protocol to patients with malignant non-hodgkin's lymphoma] (Wiadomosci lekarskie (Warsaw, Poland : 1960), 1993) Randomized controlled trial Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study (European journal of haematology, 1991) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SIROLIMUS	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT00671112 — Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (TERMINATED) PHASE1 NCT00516412 — Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (COMPLETED) PHASE2 NCT01334502 — Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma (COMPLETED) PHASE1 NCT01367457 — INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus (COMPLETED) NCT01244906 — Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant (COMPLETED) PHASE2 NCT01076543 — Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma (COMPLETED) PHASE1, PHASE2 NCT02061800 — CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT01535989 — Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT00057954 — Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma (TERMINATED) PHASE2 NCT00143845 — Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant (COMPLETED) PHASE2 NCT00818961 — Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer (TERMINATED) PHASE2 NCT04644016 — Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (RECRUITING) PHASE2 NCT02566304 — Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (COMPLETED) PHASE2 NCT00423826 — Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (NO_LONGER_AVAILABLE) NCT02061800 — CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT00004145 — Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
4-PHENYLBUTYRIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABEMACICLIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACALABRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACALABRUTINIB MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACYCLOVIR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALPELISIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIKACIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ASCIMINIB Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT03595917 — ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML (RECRUITING) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	8 trials 3 Trial pubs View evidence Registry trials NCT04962126 — Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (ACTIVE_NOT_RECRUITING) PHASE2 NCT02594384 — A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (COMPLETED) PHASE1 NCT02500407 — A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (COMPLETED) PHASE1, PHASE2 NCT04458922 — Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma (ACTIVE_NOT_RECRUITING) PHASE2 NCT02596971 — A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (COMPLETED) PHASE1, PHASE2 NCT04045028 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (TERMINATED) PHASE1 NCT02693535 — TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (RECRUITING) PHASE2 NCT03892525 — Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma (TERMINATED) PHASE1 Published literature Clinical trial publication Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group (British journal of haematology, 2025) Clinical trial publication Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma (Haematologica, 2025) Clinical trial publication Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study (The Lancet. Oncology, 2020) CT.gov search · Cochrane · PubMed	DGIdb	—
AVELUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENDAMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BLINATUMOMAB Repurposing	Small molecule	Approved	Strong	95	8 trials 5 Trial pubs View evidence Registry trials NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (NOT_YET_RECRUITING) PHASE3 NCT03150693 — Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (RECRUITING) PHASE3 NCT06287229 — Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab (RECRUITING) PHASE1, PHASE2 NCT07422337 — A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab (RECRUITING) NCT06317662 — Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (RECRUITING) PHASE2 NCT04872790 — Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (ACTIVE_NOT_RECRUITING) PHASE1 NCT03605589 — Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma (WITHDRAWN) PHASE1 NCT07133997 — Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia (RECRUITING) PHASE1 Published literature Clinical trial publication A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis (Blood advances, 2026) Clinical trial publication Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab (Experimental hematology, 2021) Clinical trial publication Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (Leukemia & lymphoma, 2020) Clinical trial publication Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma (Current clinical pharmacology, 2018) Clinical trial publication Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016) CT.gov search · Cochrane · PubMed	DGIdb	—
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT03297606 — Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
BRENTUXIMAB VEDOTIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIGATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUSULFAN Repurposing	Small molecule	Approved	Strong	95	8 trials 1 Meta-analysis 2 RCT View evidence Registry trials NCT00143845 — Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant (COMPLETED) PHASE2 NCT02836639 — BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma (UNKNOWN) PHASE2 NCT00238433 — Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma (COMPLETED) PHASE2 NCT00003661 — Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer (COMPLETED) PHASE2 NCT01961063 — Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (ACTIVE_NOT_RECRUITING) PHASE1 NCT01244906 — Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant (COMPLETED) PHASE2 NCT00818961 — Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer (TERMINATED) PHASE2 NCT04644016 — Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (RECRUITING) PHASE2 Published literature Systematic review Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review (Cancer science, 2021) Randomized controlled trial High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix) (BMC cancer, 2016) Randomized controlled trial Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial (The Lancet. Oncology, 2014) CT.gov search · Cochrane · PubMed	DGIdb	—
CABOZANTINIB S-MALATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CEMIPLIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CERITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CETUXIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
ALDESLEUKIN	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ALLOPURINOL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ASPARAGINASE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BENDAMUSTINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BEVACIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BLEOMYCIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BORTEZOMIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BUSULFAN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CARBOPLATIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CHLORAMBUCIL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CYTARABINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DAUNORUBICIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DAUNORUBICIN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DETUMOMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DOCETAXEL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DOXORUBICIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ENZASTAURIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
EPOETIN BETA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
EPRATUZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GALIXIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IBRITUMOMAB TIUXETAN	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IBRUTINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IDARUBICIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IFOSFAMIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
INOTUZUMAB OZOGAMICIN	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IRON SUCROSE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LENALIDOMIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LENOGRASTIM	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LEUCOVORIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LEUCOVORIN CALCIUM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
4-PHENYLBUTYRIC ACID Repurposing via BCL2	Small molecule	Approved	Strong	95	—	DGIdb	—
ABEMACICLIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
ACALABRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
ACALABRUTINIB MALEATE Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACYCLOVIR Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALPELISIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIKACIN Repurposing via B2M	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ASCIMINIB Repurposing via BCR	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT03595917 — ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML (RECRUITING) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing via BCR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ATEZOLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	8 trials 3 Trial pubs View evidence Registry trials NCT04962126 — Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (ACTIVE_NOT_RECRUITING) PHASE2 NCT02594384 — A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (COMPLETED) PHASE1 NCT02500407 — A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (COMPLETED) PHASE1, PHASE2 NCT04458922 — Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma (ACTIVE_NOT_RECRUITING) PHASE2 NCT02596971 — A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (COMPLETED) PHASE1, PHASE2 NCT04045028 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (TERMINATED) PHASE1 NCT02693535 — TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (RECRUITING) PHASE2 NCT03892525 — Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma (TERMINATED) PHASE1 Published literature Clinical trial publication Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group (British journal of haematology, 2025) Clinical trial publication Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma (Haematologica, 2025) Clinical trial publication Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study (The Lancet. Oncology, 2020) CT.gov search · Cochrane · PubMed	DGIdb	—
AVELUMAB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
BENDAMUSTINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BLINATUMOMAB Repurposing via BCR	Small molecule	Approved	Strong	95	8 trials 5 Trial pubs View evidence Registry trials NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (NOT_YET_RECRUITING) PHASE3 NCT03150693 — Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (RECRUITING) PHASE3 NCT06287229 — Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab (RECRUITING) PHASE1, PHASE2 NCT07422337 — A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab (RECRUITING) NCT06317662 — Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (RECRUITING) PHASE2 NCT04872790 — Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (ACTIVE_NOT_RECRUITING) PHASE1 NCT03605589 — Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma (WITHDRAWN) PHASE1 NCT07133997 — Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia (RECRUITING) PHASE1 Published literature Clinical trial publication A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis (Blood advances, 2026) Clinical trial publication Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab (Experimental hematology, 2021) Clinical trial publication Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (Leukemia & lymphoma, 2020) Clinical trial publication Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma (Current clinical pharmacology, 2018) Clinical trial publication Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016) CT.gov search · Cochrane · PubMed	DGIdb	—
BORTEZOMIB Repurposing via BCL2	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing via BCR	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT03297606 — Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing via BCR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
BRENTUXIMAB VEDOTIN Repurposing via BCL2	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIGATINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
BUSULFAN Repurposing via BCR	Small molecule	Approved	Strong	95	8 trials 1 Meta-analysis 2 RCT View evidence Registry trials NCT00143845 — Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant (COMPLETED) PHASE2 NCT02836639 — BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma (UNKNOWN) PHASE2 NCT00238433 — Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma (COMPLETED) PHASE2 NCT00003661 — Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer (COMPLETED) PHASE2 NCT01961063 — Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (ACTIVE_NOT_RECRUITING) PHASE1 NCT01244906 — Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant (COMPLETED) PHASE2 NCT00818961 — Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer (TERMINATED) PHASE2 NCT04644016 — Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (RECRUITING) PHASE2 Published literature Systematic review Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review (Cancer science, 2021) Randomized controlled trial High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix) (BMC cancer, 2016) Randomized controlled trial Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial (The Lancet. Oncology, 2014) CT.gov search · Cochrane · PubMed	DGIdb	—
CABOZANTINIB S-MALATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing via BCL2	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CEMIPLIMAB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—

Natural Products

77 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Links
Vitamin D3 Natural product Meta Analysis Review: there is a consistently strong inverse correlations with solar… Human Study Sun exposure may protect against non-Hodgkin lymphoma. Human Study Sunlight has a protective effect against non-Hodgkin lymphoma.	Nutraceutical	Phase III	Emerging	10	8 trials View evidence Registry trials NCT06508099 — Vitamin A and D Supplementation in Allogeneic HCT (RECRUITING) PHASE2 NCT01131221 — S8947-9800-9911-0016A Vitamin D Insufficiency in Determining Prognosis in Patients With Newly Diagnosed Follicular Lymphoma (COMPLETED) NCT01582932 — Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis (COMPLETED) PHASE1 NCT01787409 — Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency (ACTIVE_NOT_RECRUITING) NA NCT04442412 — Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy (RECRUITING) PHASE3 NCT02553447 — Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency (COMPLETED) NA NCT07366450 — High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma (NOT_YET_RECRUITING) NA NCT05018988 — Vitamin D in School Children (UNKNOWN) NA CT.gov search · Cochrane · PubMed	PubChem
Vitamin C Natural product Meta-analysis Micronutrient Intake and Risk of Hematological Malignancies in Adults:… Meta Analysis Review: there is a consistently strong inverse correlations with solar… Human Study Sun exposure may protect against non-Hodgkin lymphoma.	Nutraceutical	Phase III	Emerging	10	7 trials 1 Meta-analysis View evidence Registry trials NCT00626444 — Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) (TERMINATED) PHASE2 NCT05343611 — Chocolate and Physical Exercise to Reduce Malnutrition in Pre-dementia Aged People (UNKNOWN) NA NCT02961816 — Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma (WITHDRAWN) PHASE2 NCT03418038 — Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (RECRUITING) PHASE2 NCT05305456 — Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19 (COMPLETED) PHASE3 NCT03161223 — Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma (RECRUITING) PHASE1, PHASE2 NCT06114498 — Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction (ACTIVE_NOT_RECRUITING) Published literature Meta-analysis Micronutrient Intake and Risk of Hematological Malignancies in Adults: A Systematic Review and Meta-analysis of Cohort Studies (Nutrition and cancer, 2018) CT.gov search · Cochrane · PubMed	PubChem
Magnesium Natural product Human Study Plasma magnesium is inversely associated with Epstein-Barr virus load i…	Nutraceutical	Preclinical	Emerging	10	3 pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Garlic Natural product In Vitro Study Allicin, a highly active component from freshly crushed garlic, induces…	Food compound	Phase II	Emerging	10	1 trials View evidence Registry trials NCT00455416 — Dietary Intervention in Follicular Lymphoma (UNKNOWN) PHASE2 CT.gov search · Cochrane · PubMed	PubChem
Omega-3 Fatty Acids Natural product Human Study Exposure to phenoxyacetic acids and glyphosate as risk factors for non-… Commentary Reinotids (vitamin A) and EPA may work synergistically to inhibit mantl…	Nutraceutical	Phase III	Emerging	10	6 trials View evidence Registry trials NCT00455416 — Dietary Intervention in Follicular Lymphoma (UNKNOWN) PHASE2 NCT04645927 — Clinical Trial to Study the Effects of Dietary Flax Beverage on Memory and Cognition (COMPLETED) NA NCT03569202 — Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye (COMPLETED) NA NCT03483090 — Investigating the Effect of Deep Sea Krill Oil Supplementation in Osteoarthritis of the Knee (COMPLETED) PHASE2 NCT03169790 — QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (WITHDRAWN) PHASE1, PHASE2 NCT00146211 — TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	PubChem
Curcumin Natural product Human Study Rice bran arabinoxylan and curcumin therapy may be of benefit to patien… Transgenic Animal Study Curcumin induces programmed cell death and inhibits growth of human Bur… In Vitro Study Curcumin (from Turmeric) increases the efficacy of chemotherapeutic age…	Food compound	Phase II	Emerging	7	1 trials View evidence Registry trials NCT00969085 — Trial of Curcumin in Cutaneous T-cell Lymphoma Patients (WITHDRAWN) PHASE2 CT.gov search · Cochrane · PubMed	PubChem
Resveratrol Natural product Human Study There is a risk excess of Non-Hodgkin's lymphoma observed in telec… In Vitro Study Curcumin enhances programmed cell death in Epstein-Barr Virus transform… In Vitro Study Resveratrol combats follicular lymphoma cells.	Food compound	Phase II	Emerging	7	1 trials View evidence Registry trials NCT00455416 — Dietary Intervention in Follicular Lymphoma (UNKNOWN) PHASE2 CT.gov search · Cochrane · PubMed	PubChem
Egcg Natural product Meta Analysis, Review Green tea intake may be associated with reduced risk of non-Hodgkin&#03… Human Study SV40 is associated significantly with brain tumors, bone cancers, malig… In Vitro Study A nutrient mixture, containing ascorbic acid, lysine, proline, green te…	Food compound	Preclinical	Emerging	7	1 pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Berberine Natural product In Vitro Study Anti-tumor effect of berberine on chronic lymphocytic leukemia cells. In Vitro Study Berberine affects mitochondrial activity and cell growth of leukemic ce… In Vitro Study Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma b…	Botanical	Preclinical	Emerging	7	2 pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Moringa Natural product In Vitro Study Cytotoxic and apoptotic effects of different extracts of Moringa oleife… In Vitro Study Effect of microvesicles from Moringa oleifera containing miRNA on proli…	Botanical	Preclinical	Emerging	7	1 pubs View evidence CT.gov search · Cochrane · PubMed	—
Melatonin Natural product In Vitro Study Melatonin increases the chemosensitivity of diffuse large B-cell lympho… In Vitro Study Melatonin is a promising in vitro anti-tumour agent.	Nutraceutical	Preclinical	Emerging	7	6 pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Quercetin Natural product In Vitro Study Quercetin induces apoptosis and autophagy in primary effusion lymphoma… In Vitro Study Quercetin may overcome chemotherapy-resistance in chronic lymphocytic l…	Food compound	Phase II	Emerging	7	1 trials View evidence Registry trials NCT00455416 — Dietary Intervention in Follicular Lymphoma (UNKNOWN) PHASE2 CT.gov search · Cochrane · PubMed	PubChem
Valerian Natural product Human Study Verbena officinalis essential oil and its component citral has apoptoic…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Ashwagandha Natural product Review Overview of the anticancer activity of withaferin A, an active constitu…	Ayurvedic	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	PubChem
Andrographis Natural product In Vitro Study Andrographis contains a compound which induces mitochondrial-mediated a… In Vitro Study Andrographolide inhibits Burkitt's lymphoma by binding JUN and CAS…	Botanical	Phase III	Emerging	7	1 trials View evidence Registry trials NCT01805791 — A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis (TERMINATED) PHASE3 CT.gov search · Cochrane · PubMed	PubChem
Licorice Natural product In Vitro Study The current study demonstrated that licochalcone C may be a potential a…	Botanical	Preclinical	Emerging	2	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Cannabidiol Natural product In Vitro Study The evaluation of Cannabidiol's effect on the immunotherapy of Bur…	Food compound	Preclinical	Emerging	2	3 pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Artesunate Natural product Animal Study, In Vitro Study Artesunate demonstrated potent apoptosis-inducing effects across a broa… In Vitro Study Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosi… In Vitro Study Artesunate inhibits the proliferation of Burkitt's lymphoma cells.	Nutraceutical	Approved	Emerging	0	4 trials View evidence Registry trials NCT01122134 — Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment (UNKNOWN) NCT01828333 — Malaria Treatment With Injectable ArteSunate (COMPLETED) NCT01805232 — Intravenous Artesunate and Malaria (UNKNOWN) PHASE4 NCT06263582 — Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	—
EGCG (Epigallocatechin Gallate) Natural product In Vitro Study Curcumin induces programmed cell death in chronic lymphocytic leukemia… In Vitro Study EGCG inhibits the proliferation of malignant lymphoma cells. In Vitro Study Green tea contains phytochemicals (e.g. EGCG) which exhibit significant…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Fruit: All Natural product Human Study Diet and nutrient intakes and risk of non-hodgkin’s lymphoma in Connect… Human Study Vegetables and perhaps fruits could help lower the risks of non-Hodgkin… Meta Analysis, Review Combined fruit and vegetable consumption was associated with decreased…	Nutraceutical	Preclinical	Emerging	0	1 trials View evidence Registry trials NCT00726934 — The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients (COMPLETED) NA CT.gov search · Cochrane · PubMed	—
Vegetables: All Natural product Human Study Diet and nutrient intakes and risk of non-hodgkin’s lymphoma in Connect… Human Study Vegetables and perhaps fruits could help lower the risks of non-Hodgkin…	Nutraceutical	Preclinical	Emerging	0	—	—
Oridonin Natural product Animal Study, In Vitro Study Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-ger… Animal Study, In Vitro Study These findings suggest that oridonin may have promising therapeutic app…	Nutraceutical	Preclinical	Emerging	0	—	—
Honokiol Natural product Animal Study, In Vitro Study Honokiol causes considerable induction of apoptosis in lymphoid maligna… In Vitro Study Honokiol is a potent inducer of apoptosis in B-CLL cells.	Nutraceutical	Preclinical	Emerging	0	—	—
Flavonoids Natural product In Vitro Study A higher intake of flavonoids may be associated with lower non-Hodgkin… In Vitro Study Effect of baicalin on pyroptosis of diffuse large B-cell lymphoma cell…	Nutraceutical	Preclinical	Emerging	0	—	—
Sumac Natural product In Vitro Study An extract from Rhus verniciflua Stokes (Sumac) is capable of inhibitin… In Vitro Study An extract of Rhus verniciflua stokes (Sumac) inhibits cell growth and…	Nutraceutical	Preclinical	Emerging	0	—	—
Hops Natural product In Vitro Study Hops contains a compound, demethylxanthohumol, which induces programmed…	Nutraceutical	Preclinical	Emerging	0	—	—
St. John's Wort Natural product In Vitro Study Hyperforin (a fat-soluble compound from St. John's wort) may impro… In Vitro Study Hyperforin, a compound found with St. Johns wort, have anticancer activ…	Botanical	Preclinical	Emerging	0	—	PubChem
Cruciferous Vegetables Natural product Meta Analysis, Review Combined fruit and vegetable consumption was associated with decreased… Human Study Vegetables and perhaps fruits could help lower the risks of non-Hodgkin…	Nutraceutical	Preclinical	Emerging	0	—	—
Gc Protein-Derived Macrophage Activating Factor (GcMAF) Natural product Human Study The clinical cases presented here reinforce the hypothesis that GcMAF c… Human Study Exposure to phenoxyacetic acids and glyphosate as risk factors for non-… Human Study Glyphosate pesticide (Roundup) exposure is a risk factor for non-Hodgki…	Nutraceutical	Preclinical	Emerging	0	—	—
Cannabis Natural product Human Study Cannabinoids may have a therapeutic role to play in treating mantle cel…	Nutraceutical	Preclinical	Emerging	0	—	—
Mistletoe Natural product Human Study Mistletoe extract is known to induce apoptosis and immunactivation in c…	Nutraceutical	Preclinical	Emerging	0	—	—
Rice Bran Natural product Human Study Rice bran arabinoxylan and curcumin therapy may be of benefit to patien…	Nutraceutical	Preclinical	Emerging	0	—	—
Alpha-Carotene Natural product Human Study This study indicates that higher serum carotenoid levels might be inver…	Nutraceutical	Preclinical	Emerging	0	—	—
Beta-Carotene Natural product Human Study This study indicates that higher serum carotenoid levels might be inver… In Vitro Study Beta-elemene suppresses tumor growth of diffuse large B-cell lymphoma.	Nutraceutical	Preclinical	Emerging	0	—	—
Carotenoids Natural product Human Study This study indicates that higher serum carotenoid levels might be inver…	Nutraceutical	Preclinical	Emerging	0	—	—
Cryptoxanthin Natural product Human Study This study indicates that higher serum carotenoid levels might be inver…	Nutraceutical	Preclinical	Emerging	0	—	—
Citral Natural product Human Study Verbena officinalis essential oil and its component citral has apoptoic…	Nutraceutical	Preclinical	Emerging	0	—	—
Neem Natural product Human In Vitro Neem leaf extract exhibits anti-leukemic properties in patient primary…	Nutraceutical	Preclinical	Emerging	0	—	—
Beet Natural product Human: Case Report Beetroot-carrot juice can be used as an effective treatment for CLL alo…	Nutraceutical	Preclinical	Emerging	0	—	—
Carrot Natural product Human: Case Report Beetroot-carrot juice can be used as an effective treatment for CLL alo…	Nutraceutical	Preclinical	Emerging	0	—	—
Fucoidan Natural product Animal Study, In Vitro Study Antitumor activity of fucoidan against diffuse large B cell lymphoma in…	Nutraceutical	Preclinical	Emerging	0	—	—
Bromelain Natural product Animal Study, In Vitro Study Bromelain plus peroxidase reduces non-Hodgkin lymphoma progression	Nutraceutical	Preclinical	Emerging	0	—	—
Pineapple Natural product Animal Study, In Vitro Study Bromelain plus peroxidase reduces non-Hodgkin lymphoma progression	Nutraceutical	Preclinical	Emerging	0	—	—
Genistein Natural product Animal Study Genistein increases the efficacy of fludarabine in inducing cell death…	Food compound	Preclinical	Emerging	0	—	PubChem
Shikonin Natural product Animal Study, In Vitro Study Shikonin may be an encouraging chemotherapeutic agent in the clinical t…	Nutraceutical	Preclinical	Emerging	0	—	—
Cottonseed Oil (Gossypol) Natural product Animal Study Vitamin D and gossypol appear to reduce lymphocyte content in Chronic L…	Nutraceutical	Preclinical	Emerging	0	—	—
Lysine Natural product In Vitro Study A nutrient mixture, containing ascorbic acid, lysine, proline, green te…	Nutraceutical	Preclinical	Emerging	0	—	—
Proline Natural product In Vitro Study A nutrient mixture, containing ascorbic acid, lysine, proline, green te…	Nutraceutical	Preclinical	Emerging	0	—	—
Proprietary Nutrient Formulas Natural product Human Study Diet and nutrient intakes and risk of non-hodgkin’s lymphoma in Connect… In Vitro Study A nutrient mixture, containing ascorbic acid, lysine, proline, green te…	Nutraceutical	Preclinical	Emerging	0	—	—
Graviola Natural product In Vitro Study Acetogenins could be explored as selective natural inhibitors of Bcl-Xl…	Nutraceutical	Preclinical	Emerging	0	—	—
Clove Natural product In Vitro Study An integrative in silico mathematical modelling study of the anti-cance…	Nutraceutical	Preclinical	Emerging	0	—	—
Beta-Elemene Natural product In Vitro Study Beta-elemene suppresses tumor growth of diffuse large B-cell lymphoma.	Nutraceutical	Preclinical	Emerging	0	—	—
Polyphenols Natural product In Vitro Study Curcumin induces programmed cell death in chronic lymphocytic leukemia…	Nutraceutical	Preclinical	Emerging	0	—	—
Deguelin Natural product In Vitro Study Deguelin induces programmed cell death in B-cell chronic lymphocytic le…	Nutraceutical	Preclinical	Emerging	0	—	—
Devils Claw Natural product Commentary Devil's Claw may have a therapeutic role in the treatment of folli…	Nutraceutical	Preclinical	Emerging	0	—	—
Gamma-Linoleic Acid (GLA) Natural product In Vitro Study Gamma-linolenic acid induces apoptosis in B-chronic lymphocytic leukaem…	Nutraceutical	Preclinical	Emerging	0	—	—
Guarana Natural product In Vitro Study Guarana seeds have antibacterial, antineoplastic, and immunomodulatory…	Nutraceutical	Preclinical	Emerging	0	—	—
Indole-3-Carbinol Natural product In Vitro Study Indole-3-carbinol promotes apoptosis of Epstein-Barr viru-positive but…	Nutraceutical	Preclinical	Emerging	0	—	—
Lichens Natural product In Vitro Study Lichen extracts merit further research as a potential source of antican…	Nutraceutical	Preclinical	Emerging	0	—	—
Mango Natural product In Vitro Study Mangifera Indica can act promising source for anti-cancer treatment can…	Nutraceutical	Preclinical	Emerging	0	—	—
Mangiferin Natural product In Vitro Study Mangiferin combined with bortezomib can synergistically inhibit the pro…	Nutraceutical	Preclinical	Emerging	0	—	—
Nisin Natural product In Vitro Study Nisin synergistically enhances the cytotoxic and apoptotic effects of r…	Nutraceutical	Preclinical	Emerging	0	—	—
Berbamine Natural product In Vitro Study Novel synthetic 4-chlorobenzoyl berbamine inhibits c-Myc expression and…	Nutraceutical	Preclinical	Emerging	0	—	—
Piceatannol Natural product In Vitro Study Piceatannol is a potent inducer of apoptosis in the lymphoma cell line…	Nutraceutical	Preclinical	Emerging	0	—	—
Plumbagin Natural product In Vitro Study Plumbagin induces apoptosis in diffuse large B-cell lymphoma.	Nutraceutical	Preclinical	Emerging	0	—	—
Pterostilbene Natural product In Vitro Study Pterostilbene induces apoptosis and cell cycle arrest in diffuse large…	Nutraceutical	Preclinical	Emerging	0	—	—
Vitamin a Natural product Meta Analysis Review: there is a consistently strong inverse correlations with solar… Human Study Sun exposure may protect against non-Hodgkin lymphoma. Human Study Sunlight has a protective effect against non-Hodgkin lymphoma.	Food compound	Preclinical	Emerging	0	—	PubChem
Salvia Miltiorrhiza Natural product In Vitro Study Salvianolic acid A inhibits the growth of diffuse large B-cell lymphoma…	Nutraceutical	Preclinical	Emerging	0	—	—
Seaweed Natural product In Vitro Study Seaweeds have a high potential as a source of novel chemoprotectants.	Nutraceutical	Preclinical	Emerging	0	—	—
Stigmasterol Natural product In Vitro Study Stigmasterol reverses rituximab resistance in diffuse large B-cell lymp…	Nutraceutical	Preclinical	Emerging	0	—	—
Paeoniflorin Natural product Review The multifaceted mechanisms of Paeoniflorin in the treatment of tumors.	Nutraceutical	Preclinical	Emerging	0	—	—
Naringenin Natural product In Vitro Study These results provide evidence that narigenin's antitumor activity…	Food compound	Preclinical	Emerging	0	—	PubChem
Tripterygium Wilfordii Natural product In Vitro Study Triptolide inhibits transcription factor NF-kappa B, which translates i…	Nutraceutical	Preclinical	Emerging	0	—	—
Triptolide Natural product In Vitro Study Triptolide inhibits transcription factor NF-kappa B, which translates i…	Nutraceutical	Preclinical	Emerging	0	—	—
Catechin Natural product In Vitro Study Turmeric and green tea have significant apoptic effects in chronic lymp…	Nutraceutical	Preclinical	Emerging	0	—	—
Anandamide Natural product Effects of Cannabidiol, ∆9-Tetrahydrocannabinol, and WIN 55-212-22 on t… Validating the anti-lymphoma pharmacodynamic actions of the endocannabi… Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin ly…	Food compound	Preclinical	Emerging	0	—	PubChem
Wogonin Natural product	Nutraceutical	Preclinical	Emerging	0	—	—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.